Paris (ots/PRNewswire) - - Findings set foundation to drive recommendations for enhancing care - Sanofi announced today the first results of the TEENs Registry Study, the largest contemporary real-world study of the care of nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings not only ...
Paris (ots/PRNewswire) - Sanofi announced today that Lyxumia(R) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when ...
Paris (ots/PRNewswire) - - In EDITION JP I and II, investigational Toujeo(R)demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus(R)- Sanofi announced today full results from EDITION JP I and EDITION JP II that showed Toujeo(R) (insulin glargine ...
Paris, France (ots/PRNewswire) - - New results for Toujeo(R)(insulin glargine [rDNA origin] injection, 300 U/mL; "U300") from EDITION I/II/III meta-analysis, EDITION III, IV, JP 1 and JP 2 studies are among over 65 abstracts to be presented - Sanofi announced today that new data on U300, Lyxumia(R) (lixisenatide) ...
Paris (ots/PRNewswire) - - Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal - Sanofi announced today the results of a 24-week Phase IIIb clinical study showing that Lyxumia(R) (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or ...
Paris (ots/PRNewswire) - Sanofi announced today at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, the CE Mark of JuniorSTAR(R), a new halfunit insulin reusable pen that can be used with Lantus(R) (insulin glargine), Apidra(R) (insulin glulisine) or Insuman(R) ...
Paris (ots/PRNewswire) - - Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin - Sanofi announced today new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia(R) (lixisenatide), when added to basal insulin, were greatest in patients with ...
Paris (ots/PRNewswire) - - First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes - Sanofi announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the manufacturing and distribution of Lyxumia(R) (lixisenatide) ...
Paris (ots/PRNewswire) - - EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus(R)- - Topline results of EDITION II consistent with EDITION I findings - Sanofi announced today that the first phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with ...
Paris (ots/PRNewswire) - Sanofi announced today that clinical data highlighting the company's ongoing commitment to advancing diabetes care will be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions in Chicago, USA (June 21-25, 2013). In total, more than 60 abstracts representing new data ...
Paris (ots/PRNewswire) - - Worldwide invitation to create and submit concepts for a potential next-generation insulin delivery device - Sanofi announced today that it is accepting submissions for Ignite: The Diabetes Ideas Challenge ("Ignite Challenge"). The web-based Ignite Challenge invites patients, caregivers, designers, engineers, and innovators from around the ...
Paris (ots/PRNewswire) - - Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist - Sanofi announced today that the European Commission has granted Marketing Authorisation in Europe for Lyxumia(R) (lixisenatide). Lyxumia(R), the first once-daily prandial GLP-1 receptor agonist, is ...